General Meeting

On 02 March 2015, we announced the completion of our major three-part transaction with Novartis.

Animation showing the Novartis transaction

As a result, GSK has acquired Novartis’s global Vaccines business (excluding influenza vaccines), created a new world-leading Consumer Healthcare joint venture with Novartis and divested our marketed Oncology business to Novartis.

Previously published documents regarding the transaction are below: